Kazia Therapeutics (KZIA) Change in Receivables (2016 - 2021)
Kazia Therapeutics (KZIA) posted Change in Receivables of $6303.0 for Q4 2021, down 99.13% on a QoQ basis from $727538.1 in Q4 2020, and down 99.13% year-over-year from $727538.1 in Q4 2020.
Kazia Therapeutics (KZIA) Change in Receivables (2016 - 2021) Analysis & Trends
Kazia Therapeutics' Change in Receivables history runs 3 years deep, the most recent figure standing at $6303.0 for Q4 2021.
- Quarterly Change in Receivables fell 99.13% year-over-year to $6303.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was -$2.7 million (down 161.17% YoY) and the FY2025 annual result came in at $2.4 million, up 73736.58% from the prior year.
- Change in Receivables was $6303.0 for Q4 2021 at Kazia Therapeutics, down from $727538.1 in the prior quarter.
- Across five years, Change in Receivables topped out at $727538.1 in Q4 2020 and bottomed at $6303.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 75.30 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 2.84 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -39.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -1.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Kazia Therapeutics | 4.11 Mn | 4.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 6,302.99 |
| Dec 31, 2021 | 6,302.99 |
| Dec 31, 2020 | 727,538.12 |
| Dec 31, 2020 | 727,538.12 |
| Dec 31, 2016 | -3.39 Mn |
| Dec 31, 2016 | -3.39 Mn |